What is the official website of Novartis Deutschland ?

The official website of Novartis Deutschland is http://www.novartis.de.

What is Novartis Deutschland's cybersecurity risk score?

Novartis Deutschland has an AI-generated cybersecurity risk score of 756 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Deutschland experienced?

According to Rankiteo, Novartis Deutschland currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Deutschland been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Deutschland has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Deutschland have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Deutschland is not certified under SOC 2 Type 1.

Does Novartis Deutschland have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Deutschland does not hold a SOC 2 Type 2 certification.

Does Novartis Deutschland comply with GDPR ?

According to Rankiteo, Novartis Deutschland is not listed as GDPR compliant.

Does Novartis Deutschland have PCI DSS certification ?

According to Rankiteo, Novartis Deutschland does not currently maintain PCI DSS compliance.

Does Novartis Deutschland comply with HIPAA ?

According to Rankiteo, Novartis Deutschland is not compliant with HIPAA regulations.

Does Novartis Deutschland have ISO 27001 certification ?

According to Rankiteo,Novartis Deutschland is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Deutschland operate in ?

Novartis Deutschland operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Deutschland have ?

Novartis Deutschland employs approximately 442 people worldwide.

Does Novartis Deutschland own any subsidiaries ?

Novartis Deutschland presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Deutschland have ?

Novartis Deutschland's official LinkedIn profile has approximately 31,002 followers.

What is the NAICS classification code for Novartis Deutschland ?

Novartis Deutschland is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Deutschland have a Crunchbase profile ?

No, Novartis Deutschland does not have a profile on Crunchbase.

Does Novartis Deutschland have a LinkedIn profile ?

Yes, Novartis Deutschland maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-deutschland.

How many cybersecurity incidents has Novartis Deutschland experienced ?

As of October 6, 2026, Rankiteo reports that Novartis Deutschland has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Deutschland have ?

Novartis Deutschland has an estimated 5,773 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Deutschland faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Deutschland

Boost Score +25 with badge (5 left)

756

/1000

Fair

781

/1000

Fair

Novartis Deutschland Vendor Cyber Rating & Cyber Score

novartis.de

Add Your Compliance Badge

Novartis ist ein führendes Pharmaunternehmen in Deutschland mit ca. 2.600 Mitarbeitenden an verschiedenen Standorten und mehr als 70.000 Mitarbeitenden weltweit. Wir sind angetrieben davon, Medizin neu zu denken, um das Leben von Menschen zu verbessern. Wir nutzen Wissen, Kreativität und Engagement unserer Mitarbeitenden, die Chancen wissenschaftlicher Forschung sowie digitale Technologien, um wegweisende Therapien in verschiedenen Gesundheitsbereichen zu entwickeln. Wir wollen die besten Talente an uns binden und bieten ihnen den Arbeitsplatz und die Entwicklungsmöglichkeiten eines internationalen Marktführers. Als innovatives Unternehmen ist Novartis ein attraktiver Arbeitgeber für Absolventinnen und Absolventen unterschiedlichster

Novartis Deutschland

Novartis Deutschland CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Deutschlan...

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Deutschland Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Deutschland

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Deutschland in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Deutschland in 2026.

Incident Types Novartis Deutschland vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Deutschland in 2026.

Incident History - Novartis Deutschland (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Deutschland Subsidiaries

Novartis Deutschland

Pharmaceutical Manufacturing

Website: http://www.novartis.de

Company Size: 442

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Loading…

Novartis Deutschland Similar Companies

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Johnson & Johnson Innovative Medicine

jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Servier

servier.com

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants and is distributed across six continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

Loading…

NEWS

Novartis Deutschland CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

November 08, 2023 08:00 AM

Top 10 CISOs in EMEA

We consider some of the leading CISOs within the EMEA region who are committed to developing and implementing security policies to protect...

Read Article

September 26, 2011 07:00 AM

Novartis Vaccine Manufacturing Facility

Novartis has begun production at its new vaccine manufacturing facility in Marburg, Germany in April 2011. The plant produces rabies and...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-105761

SUMMARY

Dify is an open-source LLM app development platform. Prior to 1.16.0, the PUT /console/api/apps/<app_id>/server endpoint in api/controllers/console/app/mcp_server.py used AppMCPServerController.put() to retrieve an AppMCPServer by the client-supplied server ID without verifying that the server belonged to the requested application and tenant. An authenticated workspace member could therefore change another application's MCP server status and parameters, potentially redirecting data or disabling the service. This issue is fixed in version 1.16.0.

Published

Date2026-10-05

Updated

Date2026-10-05

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:L

Impact Score

4.2

Exploitability

2.8

REFERENCES

CVE-2026-105760

SUMMARY

vLLM is an inference and serving engine for large language models. Prior to 0.30.0, a caller can use the request-level media_io_kwargs field to select the GLMGA video backend and supply large values for the fps and max_frames options without a strict work ceiling. GLMGA constructs and deduplicates an attacker-sized pre-decode frame-index list, allowing a compact request and tiny valid video to consume disproportionate CPU time and memory in the shared media-loading executor. This issue is fixed in version 0.30.0.

Published

Date2026-10-05

Updated

Date2026-10-05

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-105759

SUMMARY

vLLM is an inference and serving engine for large language models. Prior to 0.30.0, the Rust frontend's track_http_metrics middleware records the raw HTTP method token as a Prometheus label for requests reaching registered routes. An unauthenticated attacker can send unique arbitrary method tokens to unguarded routes such as /tokenize, causing Prometheus's Family::get_or_create function to permanently create counter and histogram label sets. Those label sets increase process memory usage and enlarge the /metrics response until the service or monitoring path is exhausted. This issue is fixed in version 0.30.0.

Published

Date2026-10-05

Updated

Date2026-10-05

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.2

REFERENCES

CVE-2026-105758

SUMMARY

vLLM is an inference and serving engine for large language models. From 0.24.0 until 0.30.0, the Qwen2VLVideoBackend and Qwen3VLVideoBackend classes accept request-level values for the media_io_kwargs.video.max_frames and media_io_kwargs.video.fps fields without enforcing server-side ceilings. An unauthenticated caller can submit these values to the /tokenize endpoint, causing the sampler to decode every frame selected from attacker-controlled video input, consume disproportionate frontend memory, and potentially terminate the API process before scheduling or admission control. The Rust frontend is not affected because it rejects the media_io_kwargs field. This issue is fixed in version 0.30.0.

Published

Date2026-10-05

Updated

Date2026-10-05

RISK INFORMATION (Score: 5.3)

cvss3

Base Score: 5.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:L

Impact Score

1.4

Exploitability

3.9

REFERENCES

CVE-2026-105757

SUMMARY

vLLM is an inference and serving engine for large language models. Prior to 0.30.0, structured-output request failures can escape request-scoped validation and reach the EngineCore fatal-error path. A per-request backend mismatch can re-raise a grammar compilation exception, padding produced by the ngram_gpu speculative-decoding mode can pass a negative token to guidance validation, and the Rust frontend can admit empty structured-output values that the Python frontend rejects, allowing ordinary constrained-generation requests to terminate the shared engine. This issue is fixed in version 0.30.0.

Published

Date2026-10-05

Updated

Date2026-10-05

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis Deutschland Vendor Cyber Rating & Cyber Score

Novartis Deutschland A.I CyberSecurity Scoring

Novartis Deutschland CyberSecurity News & History

Novartis Deutschland Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Deutschland

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Deutschland vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Deutschland (X = Date, Y = Severity)

Novartis Deutschland Subsidiaries

Novartis Deutschland

Novartis Deutschland Similar Companies

PT Kalbe Farma, Tbk

UCB

Lonza

Johnson & Johnson Innovative Medicine

Servier

Zydus Group

Viatris

MENARINI Group

Takeda

Novartis Deutschland CyberSecurity News

Top 10 CISOs in EMEA

Novartis Vaccine Manufacturing Facility

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis Deutschland CyberSecurity News & History

Novartis Deutschland Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Deutschland

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Deutschland vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Deutschland (X = Date, Y = Severity)

Novartis Deutschland Subsidiaries

Novartis Deutschland

Novartis Deutschland Similar Companies

PT Kalbe Farma, Tbk

UCB

Lonza

Johnson & Johnson Innovative Medicine

Servier

Zydus Group

Viatris

MENARINI Group

Takeda

Novartis Deutschland CyberSecurity News

Top 10 CISOs in EMEA

Novartis Vaccine Manufacturing Facility

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo